Shire Finally Gets Resuscitated Adult ADHD Drug Back On Track With FDA

The 16-hour ADHD candidate SHP465 (SPD465) is being aimed at adults, but FDA wants a study in children, which will kick off in August and may allow a launch by the end of 2017, Shire says.